title: [Vulvovaginal candidiasis: a therapeutic approach].
abstract: The vulvovaginal candidiasis represents, after the bacterial vaginosis, the most frequent cause of vaginal affection. It is esteemed that around the 75% of the women of reproductive age suffered from an episode of vulvovaginitis from candida and 40-45% have had more episodes, of which 10-20% in complicated form. The kind of candida more frequently isolated in the vagina of symptomatic women is the Candida albicans: in the 10-20% of the cases the agent is present in absence of symptomatology, and we can almost consider it a saprophytic. On the other hand, always with greater frequency fetterses can be isolated of not albicans Candida, particularly the tropicalis and the glabrata kind, usually resistant to the common therapies. The classification of the vulvovaginal candidiasis proposed by Sobel, and by now universally approved, foresees 2 clinical forms of vulvovaginal candidiasis, the vulvovaginitis from not complicated candida (VVC) and the vulvovaginitis from complicated candida (VVCC): different for pathogenesis, elapsed clinical, symptomatology and frequency. They have to be considered in the substance 2 different nosological entities, and they request a diagnostic approach and a well different therapeutic appointment. In this study we will shortly reassume the principal characteristics of it, detaining us on the most recent acquisitions in theme of therapy. The base medicines of ac. boric, to parity of effectiveness, seem to introduce the most contained cost and the best compliance, and they offer him to a complementary use or, in some cases, alternative to the more you consolidate therapies with azoli.
authors.affiliation: UOC Ginecologia e Ostetricia, Dipartimento Materno Infantile, A.C.O. San Filippo Neri, Roma. franbatt@aliceposta.it
authors.forename: F
authors.initials: F
authors.lastname: Battaglia
authors.forename: L
authors.initials: L
authors.lastname: Mariani
authors.forename: F
authors.initials: F
authors.lastname: Anglana
authors.forename: V
authors.initials: V
authors.lastname: Milite
authors.forename: M
authors.initials: M
authors.lastname: Quattrini
authors.forename: F
authors.initials: F
authors.lastname: Plotti
authors.forename: F
authors.initials: F
authors.lastname: Tomao
authors.forename: G
authors.initials: G
authors.lastname: Plotti
mesh_terms: D000935:Antifungal Agents / Q000627:therapeutic use*; D001888:Boric Acids / Q000191:economics / Q000627:therapeutic use*; D002176:Candida albicans / Q000302:isolation & purification; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy* / Q000382:microbiology / Q000503:physiopathology; D005260:Female; D006801:Humans
chemical_list: D000935:Antifungal Agents; D001888:Boric Acids; C032688:boric acid